Old Classic Drug Advertisments Volume 1

[Chip (OP)]

A Century of Selling Chemistry: Pharmaceutical Advertising, 1885–1970s

A curated collection tracing how the same rhetorical playbook — name the problem, sell the solution — persisted across a hundred years of drug marketing, from unregulated Victorian tonics to "syndrome"-branded tranquilizers.


1885 — Cocaine Toothache Drops
Lloyd Manufacturing Co., Albany NY

Marketed directly to parents for children's dental pain, sold by any druggist, no prescription required. This predates virtually all US drug regulation — the Pure Food and Drug Act (1906) and Harrison Act (1914) were both decades away. The cheerful children's-illustration style does a lot of work normalising an unregulated narcotic as a household remedy.


1901 — Heroin-Hydrochloride
Bayer Pharmaceutical Products

The famous one. Marketed as a cough suppressant for bronchitis, phthisis, and whooping cough, pitched as cheaper and more efficient than competing remedies, dosed in grains. Bayer trademarked "Heroin" as a brand name before addiction data forced reformulation and eventual withdrawal from that indication.


c.1940 — "Stay Fit and Slim" (Amphetamine Sulphate)
Publisher unattributed / repro via The Advertising Archives

Pitches amphetamine sulphate as a slimming aid enabling women to "slim while you do the housework." The stated dose — "a couple of grammes daily" — is wildly implausible: therapeutic doses of the era (Benzedrine tablets) were 5–10mg, meaning this figure is roughly 100–200x a normal dose. Likely either advertising hyperbole, a grains/grammes transcription error (2 grains ≈ 130mg would be far more plausible), or an inaccuracy introduced in a later reproduction/recreation of the original ad.


1950s — "Why is this woman tired?" (Dexedrine)
Smith, Kline & French Laboratories

Pitched to physicians, not patients: distinguishes physical tiredness (treat with rest) from mental/emotional fatigue in "housewives... crushed under a load of dull, routine duties," for which Dexedrine is offered as the remedy. An early instance of medicalising domestic drudgery — a direct forerunner of the "mother's little helper" marketing later associated with benzodiazepines.


c.1950s-60s — "To Brighten the Outlook in Menstrual Dysfunction" (Dexedrine Sulfate)
Smith, Kline & French Laboratories

Reframes normal menstrual mood and energy fluctuation as "depressive symptoms" and "psychogenic fatigue" requiring a CNS stimulant. Dose stated (5mg) is consistent with genuine therapeutic dosing of the period — unlike the "Stay Fit and Slim" ad, this one is internally plausible as real clinical/trade advertising.


1960s — "Drug Evaders" (Thorazine / Stelazine / Compazine Concentrate)
Smith Kline & French Laboratories

Institutional advertising aimed squarely at medication compliance anxiety: patients "notoriously" cheek or dispose of tablets, so liquid concentrate is sold as harder to evade. Frames the patient as an adversary to be out-manoeuvred rather than a person being treated.


1960s — "They come around three or four times a day and try to poison me..." (Stelazine Concentrate)
Smith Kline & French Laboratories

Widely cited as one of the most tone-deaf pharmaceutical ads ever run. The hooded figures are Spanish Nazareno Holy Week penitential robes, not Ku Klux Klan regalia — but the visual is close enough to Klan imagery that the ad has been criticised for decades on that basis regardless of the original intent. Copy pairs a patient's paranoid ideation with genuinely menacing imagery, framing the fear itself as pathology while selling concentrate as a compliance tool for "insuring the medication has been taken."


1970 — "In Anxiety—Relaxation Rather Than Drowsiness" (Stelazine)
Smith Kline & French Laboratories

A softer, later-register companion ad — aimed at general/outpatient practice rather than institutional settings — attempting to rebrand a phenothiazine antipsychotic as a gentle, non-sedating anxiolytic. A considerable stretch given the extrapyramidal and other effects disclosed in SKF's own contemporaneous literature.


Undated — "Thorazine can allay the suffering caused by the pain of severe bursitis"
Smith, Kline & French Laboratories

Genre-bending use of chlorpromazine for a non-psychiatric indication — sold not as pain relief but as "serene detachment" from pain, explicitly quoting clinicians describing it as putting "a curtain between them and their pain." Glamour-shot styling, aimed at general practice, not institutional psychiatry.


Undated — "Now He Can Cope..." / "Now She Can Cope..." (Butisol Sodium)
McNeil Laboratories, Fort Washington, PA

Matched campaign pair, identical copy block ("daytime sedative for everyday situational stress," 15–30mg t.i.d./q.i.d.), differentiated only by gendered crisis imagery: his version shows office/domestic chaos, hers shows her tied up by a child with string amid scattered toys. Butisol is a barbiturate, not a benzodiazepine — meaningfully more dangerous in overdose and dependence than the near-identical "cope with everyday stress" marketing that benzodiazepines would adopt within a few years. This pair sits at the hinge point of that transition.


1970s — "The Battered Parent Syndrome" (Miltown / Meprobamate)
Wallace Pharmaceuticals, Cranbury NJ

Peak "invented syndrome" marketing: coins a pop-psychology label for ordinary parental exhaustion, explicitly naming the feminist-adjacent role conflict between education/autonomy and domestic expectation as the causative pathology. Notably candid copy admits Miltown is "no substitute for a week in Bermuda, or for emotional readjustment" but "makes the latter easier" — an unusually open acknowledgment that the drug is a stopgap rather than a fix.


Undated — "You Can't Set Her Free. But You Can Help Her Feel Less Anxious." (Serax / Oxazepam)
Wyeth Laboratories, Philadelphia PA

The most self-aware ad in the set: explicitly states the drug "cannot change her environment," offering only to relieve anxiety, tension, and irritability so she can better "cope with day-to-day problems." Same domestic-confinement framing as the Butisol and Miltown ads, but stated almost as a selling point rather than something to obscure.


1960s — "When the Patient Lashes Out Against 'Them'" (Thorazine)
Smith Kline & French Laboratories

The most explicit behavioural-control framing in the SKF set: the giant unblinking eye and fleeing/attacking male figure visually equate psychosis with violence, while the copy sells Thorazine on speed of subduing "assaultive or destructive behavior" before pivoting to its slower-acting antipsychotic effects on delusions and hallucinations. Marked "a reminder advertisement" — trade-journal maintenance copy aimed at physicians already prescribing, not an initial pitch. Sits alongside the "Drug Evaders" and hooded-figure Stelazine ads as part of the same institutional-control cluster: patient as threat to be contained first, treated second.


Undated — "Normal People Don't Need Drugs"
Anti-drug PSA, publisher unattributed

A distinct genre from the rest of this collection — not pharmaceutical advertising but a prevention-era public health poster, aimed at the illustrated-magazine youth-culture aesthetic of the early 1970s. The line quietly does the same rhetorical work as the pharma ads above, in reverse: it defines "normal" by absence of drug use, implicitly pathologising anyone who doesn't fit that frame — the exact same normal/abnormal boundary-drawing the SKF and McNeil ads relied on to sell prescription stimulants, sedatives, and antipsychotics to "everyday" people. Useful as a counterpoint piece: prescription drugs marketed as the solution to ordinary life, while illicit drugs are marketed against on the premise that "normal" people wouldn't need any chemical help at all.


Through-line

Taken together, this set traces a continuous chronological arc: unregulated Victorian-era opiates and cocaine sold direct to consumers → early institutional psychiatric marketing built on compliance and control → mid-century stimulants and barbiturates sold to housewives as a fix for domestic fatigue → 1960s–70s "invented syndrome" and tranquilizer marketing that becomes increasingly candid about treating the symptom of confinement rather than the confinement itself. The target of reassurance shifts throughout — sometimes the physician, sometimes the institution, sometimes, by the end, an open acknowledgment to the patient herself that nothing about her circumstances is going to change.